Updates on neoadjuvant therapy in borderline resectable pancreatic cancer
10.3760/cma.j.issn.1007-8118.2015.03.016
- VernacularTitle:临界可切除胰腺癌新辅助治疗的研究进展
- Author:
Fengzhi QU
;
Gang WANG
;
Bei SUN
;
Hongchi JIANG
- Publication Type:Journal Article
- Keywords:
Neoadjuvant therapy;
Borderline resectable pancreatic cancer (BRPC);
R0 resection
- From:
Chinese Journal of Hepatobiliary Surgery
2015;21(3):206-209
- CountryChina
- Language:Chinese
-
Abstract:
Borderline resectable pancreatic cancer (BRPC),characterized by low resectability rate and high postoperative recurrence rate,is a special kind of pancreatic cancer between resectable type and nonresectable one.Currently,the efficacy of neoadjuvant therapy for BRPC has become a hot topic in the field of pancreatic cancer.Although neoadjuvant therapy plays a critical role in obviously improving the R0 resectability rate and survival status of BRPC patients,the normalized therapeutic regimen has not been established.In this article,we overviewed the recent progress on the neoadjuvant therapy in treating BRPC.
